The alliance between the two companies was created to select specific proteins which can be manufactured into drugs that either have received orphan drug designation or have the potential to receive it. Financial details were not disclosed.
Prometic’s Plasma Protein Purification System (PPPS) technology, which was co-developed with The American Red Cross, can be applied to the recovery of certain proteins that have established therapeutic value but cannot be extracted effectively via current manufacturing practices, or that are not the focus of large plasma fractionators.
ProMetic and Kedrion will share in the revenue derived from the sales of commercialized therapeutics and will initially target Europe.